Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales @ radiantinsights. com Web: http:// www. radiantinsights. com /
Table 14: Type 2 Diabetes Mellitus, Global Pipeline Programs Targeting Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha, 2016 62 Table 15: Type 2 Diabetes Mellitus, Global, Key Features of Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha, 2016 62 Table 16: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting Glucagon, 2016 63
List of Figures:
Figure 1: Type 2 Diabetes Mellitus, Global, Innovation Trends in Product Approvals Across the Pharmaceutical Market, 1987-2014 6 Figure 2: Type 2 Diabetes Mellitus, Global, Post-Marketing-Approval Sales Performance of Firstin-Class and Non-First-in-Class Products Across Pharmaceutical Industry($ m), 2006-2013 8 Figure 3: Type 2 Diabetes Mellitus, Global, Marketed Products by Molecule Type, 2016 22 Figure 4: Type 2 Diabetes Mellitus, Global, Marketed Products by Molecular Target, 2016 23 Figure 5: Type 2 Diabetes Mellitus, Global, Pipeline Size by Therapy Area, 2016 25 Figure 6: Type 2 Diabetes Mellitus, Global, Pipeline by Stage of Development and Molecule Type, 2016 26 Figure 7: Type 2 Diabetes Mellitus, Global, Pipeline by Molecular Target and Stage of Development, 2016 27 Figure 8: Type 2 Diabetes Mellitus, Global, Pipeline Breakdown of GPCR and Protein Kinase Molecular Target, 2016 28 Figure 9: Type 2 Diabetes Mellitus, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2016 29 Figure 10: Type 2 Diabetes Mellitus, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2016 31 Figure 11: Type 2 Diabetes Mellitus, Global, Percentage Distribution of First-in-Class and Non- First-in-Class Pipeline Products by Stage of Development, 2016 32 Figure 12: Type 2 Diabetes Mellitus, Global, Percentage Distribution of First-in-Class and Non- First-in-Class Pipeline Products by Molecular Target Class, 2016 32 Figure 13: Type 2 Diabetes Mellitus, Global, Ratio of First-in-Class Targets to First-in-Class Products by Stage of Development, 2016 33 Figure 14: Type 2 Diabetes Mellitus, Global, Ratio of First-in-Class Targets to First-in-Class Products by Molecular Target, 2016 33
Browse Full Research Report @ http:// www. radiantinsights. com / research / frontier-pharmatype-2-diabetes-mellitus-gpcrs-and-protein-kinases-dominate-pipeline
https
:// www. facebook. com / RadiantInsights
https:// www. linkedin. com / company / radiant-insights https:// twitter. com / radiantinsights
https:// plus. google. com /+ Radiantinsights